| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_843659aad9c4fcabeaa8bd2c0728a181 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01P2002-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01P2004-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01P2004-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01P2004-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01P2004-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B05D7-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01G45-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04 |
| filingDate |
2013-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbc7b39c0cb6e50dba39a398bbcc417b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8922af854afa11cd2174bf85b1a94070
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3823be22ec42a527fe7bdff7675891c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49f57cf3f7291770dd06d81edb5bf4d8 |
| publicationDate |
2014-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014163221-A1 |
| titleOfInvention |
Metal oxide nanoparticle-based t1-t2 dual-mode magnetic resonance imaging contrast agent |
| abstract |
The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104758956-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020268912-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11571486-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017139653-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017245817-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104758956-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2981293-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113440624-A |
| priorityDate |
2013-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |